StageZero Life Sciences Ltd. (OTCMKTS:SZLSF – Get Rating) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 6,400 shares, a growth of 45.5% from the January 15th total of 4,400 shares. Based on an average daily volume of 4,400 shares, the days-to-cover ratio is presently 1.5 days.
StageZero Life Sciences Trading Up 5.6 %
OTCMKTS SZLSF opened at $0.05 on Friday. StageZero Life Sciences has a 12-month low of $0.04 and a 12-month high of $0.20. The company has a fifty day simple moving average of $0.05 and a two-hundred day simple moving average of $0.06. The company has a quick ratio of 0.04, a current ratio of 0.08 and a debt-to-equity ratio of 0.44.
Get
StageZero Life Sciences alerts:
About StageZero Life Sciences
(Get Rating)
StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K.
Recommended Stories
- Get a free copy of the StockNews.com research report on StageZero Life Sciences (SZLSF)
- MarketBeat Week in Review – 2/6 – 2/10
- Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
- The Bottom Is In For Cloudflare Stock
- 3 Tickers Leading a Meme Stock Revival
- Microsoft-Activision Blizzard Merger: Navigating Risk and Reward
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
StageZero生命科學有限公司(OTCMKTS:SZLSF-GET Rating)是1月份空頭股數大幅增長的目標。截至1月31日,空頭股數共有6400股,比1月15日的4400股增長了45.5%。以日均成交量4,400股計算,目前天數與回補比率為1.5天。
StageZero生命科學公司股價上漲5.6%
OTCMKTS SZLSF上週五開盤報0.05美元。StageZero生命科學的12個月低點為0.04美元,12個月高位為0.20美元。該公司的50日簡單移動均線切入位在0.05美元,200日簡單移動均線切入位在0.06美元。該公司的速動比率為0.04,流動比率為0.08,債務權益比率為0.44。
到達
StageZero生命科學警報:
關於StageZero生命科學
(獲取評級)
StageZero生命科學有限公司致力於專利分子診斷測試的開發和商業化,用於檢測疾病和個性化健康管理,重點是癌症相關適應症。其產品包括哨兵原理和科隆哨兵。該公司是由劉忠欽和K。
推薦故事
- 免費獲取StockNews.com關於StageZero生命科學(SZLSF)的研究報告
- 市場回顧周-2/6/2/10
- 為了讓拉力活下去,雪花會有艱難的雪橇嗎?
- Cloudflare股票的底部已經到來
- 引領Meme股票復甦的3個股票代碼
- 微軟與動視暴雪合併:駕馭風險與回報
接受StageZero生命科學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對StageZero生命科學和相關公司的最新新聞和分析師評級的每日簡要摘要。